EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
SEP 2024
-
EDITION 16
-
TABLES 106
-
REGIONS 13
-
SEGMENTS 9
-
PAGES 409
-
US$ 5600
-
MCP-7443
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
HIGHLIGHTS & REPORT INDEX
Global Orphan Drugs Market to Reach US$394.7 Billion by 2030
The global market for Orphan Drugs estimated at US$179.5 Billion in the year 2023, is expected to reach US$394.7 Billion by 2030, growing at a CAGR of 11.9% over the analysis period 2023-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.7% CAGR and reach US$286.3 Billion by the end of the analysis period. Growth in the Non-biologic Drugs segment is estimated at 10.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$72.3 Billion While China is Forecast to Grow at 13.1% CAGR
The Orphan Drugs market in the U.S. is estimated at US$72.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$30.2 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.0% CAGR.
Global Orphan Drugs Market - Key Trends & Drivers Summarized
Why Are Orphan Drugs Becoming Increasingly Important in Healthcare?
Orphan drugs are becoming a significant focus in the pharmaceutical industry, driven largely by the need to address rare diseases that affect a small percentage of the population but have historically been neglected due to limited market potential. These drugs are specifically developed to treat, prevent, or diagnose rare medical conditions, often called orphan or rare diseases, which affect fewer than 200,000 individuals per year in the United States. The growing awareness of rare diseases, coupled with advocacy efforts from patient groups and non-profit organizations, has put pressure on pharmaceutical companies to focus on developing treatments for these underserved conditions. Government incentives, such as market exclusivity, tax credits, and accelerated approvals, have played a crucial role in encouraging pharmaceutical companies to invest in orphan drug development.
How Is Innovation Shaping the Orphan Drugs Market?
Technological and scientific advancements have significantly boosted the development of orphan drugs, particularly through advances in genomics, personalized medicine, and biotechnology. Innovations such as CRISPR gene editing, targeted therapies, and monoclonal antibodies have revolutionized the ability to understand the underlying genetic and molecular causes of rare diseases, making it possible to create more effective and targeted treatments. Additionally, the increasing use of biomarkers for precise diagnosis and drug matching is paving the way for personalized orphan drug therapies that are tailored to the individual genetic makeup of patients. This has not only increased the efficacy of treatments but also minimized side effects, making therapies more acceptable for patients suffering from chronic, rare conditions.
How Are Changes in Healthcare Dynamics and Patient Needs Influencing Orphan Drugs?
Changing dynamics in healthcare and the evolving needs of patients are influencing the orphan drugs market in multiple ways. There is a rising recognition of the significant unmet medical needs faced by patients suffering from rare diseases, leading to an increasing number of regulatory frameworks aimed at fast-tracking the approval process for these treatments. As a result, regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly adopting measures to support quicker access to orphan drugs. Moreover, patient advocacy groups have played a key role in driving policy changes and raising awareness, which has, in turn, encouraged more clinical trials and funding in the orphan drug space. This growing awareness is also empowering patients to seek specialized care and treatments, leading to increased diagnosis rates for rare diseases and thus expanding the potential market for orphan drugs.
The Growth in the Orphan Drugs Market Is Driven by Several Factors.
The growth in the orphan drugs market is driven by several factors, including government incentives such as extended market exclusivity, grants, and reduced fees that make orphan drug development financially viable for pharmaceutical companies. Advances in biotechnology and genomics have also enabled the development of targeted therapies for rare diseases, increasing the number of potential treatments. The increasing prevalence and diagnosis rates of rare diseases, partly due to improved medical knowledge and awareness, are also contributing to the expansion of the orphan drugs market. Additionally, favorable regulatory frameworks and expedited approval processes from agencies like the FDA and EMA are helping bring orphan drugs to market faster. The role of patient advocacy groups, which actively raise funds, participate in research, and advocate for rare disease patients, is another major growth driver, as they contribute to an environment that supports innovation in orphan drug development.
SCOPE OF STUDY
The report analyzes the Orphan Drugs market in terms of US$ Million by the following Disease Type; Drug Type, and Geographic Regions/Countries:
Segments:
Drug Type (Biologics, Non-Biologics); Disease Type (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Other Disease Types).
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World..
SELECT PLAYERS
AbbVie Inc.; AstraZeneca Plc; Biogen., Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd; GSK Plc; Johnson & Johnson; Novartis AG; Pfizer Inc.; Sanofi S.A; Takeda Pharmaceutical Company Limited
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Orphan Drugs: A Beacon of Hope for Patients with Rare Diseases |
Economic Frontiers: Trends, Trials & Transformations |
EXHIBIT: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025 |
EXHIBIT 2: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025 |
EXHIBIT: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025 |
Sluggish Growth of Orphan Drugs Market: A Side-Effect of COVID-19 |
Competitive Landscape |
Orphan Drugs – Global Key Competitors Percentage Market Share in 2024 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 111 Players Worldwide in 2024 (E) |
Global Market Overview and Analysis |
Global Orphan Drugs Market to Continue Exhibiting Signs of Robust Health |
Top 10 Orphan Drugs Worldwide |
Biologics, Oncology & Hospital Pharmacies: Pulsating Segments of Global Orphan Drugs Market |
North America Clinches Commanding Share of Global Orphan Drugs Market |
Recent Market Activity |
Influencer/Product/Technology Insights |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Increasing Prevalence of Rare Diseases to Drive the Global Orphan Drugs Market |
Estimated Prevalence of Select Rare Diseases (Per 100000 Population): 2023 |
The Rise of Biopharmaceutical Industry and Growth of Orphan Drugs |
List of U.S. FDA Approved Orphan Drugs (2022-2024) |
List of Orphan Drugs Approved in Europe between 2022 and 2024 |
Advancements in Genetic and Molecular Research Transforms the Rare Disease Treatment |
Oncology's Dominance in the Orphan Drug Landscape: Expanding Horizons in Rare and Common Cancer Treatments |
EXHIBIT : Total Number of New Cancer Cases by Type: 2022 |
High Cost Associated with Orphan Drug Development - A Key Challenge |
Serious Focus on R&D Activity to Propel Market Demand |
Exhibit: Breakdown of Global R&D Pipeline Value: Orphan Drugs & Non-Orphan Drugs (2022-2026) |
Exhibit: Top Orphan Drug Companies: Percentage Share of Orphan Drugs Sales as a Percentage of Total Sales for Leading Drug Companies (2023) |
Select Recent Advancements |
Favorable Government Policies Drive Market Growth |
Technologies & Strategies to Stay Ahead of Orphan Drug Development Game |
Incentives & Guidelines Injecting Adrenaline into Orphan Drug Development Efforts |
Uptrend in Healthcare Expenditure Creates Substantial Opportunities |
EXHIBIT: World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023 |
4. GLOBAL MARKET PERSPECTIVE |
World Orphan Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Non-biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Non-biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Non-biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Oncological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Oncological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Oncological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Hematologic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Hematologic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Hematologic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Respiratory Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Endocrine Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Endocrine Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Endocrine Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
USA Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
JAPAN |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
Japan Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
CHINA |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
China Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
EUROPE |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
Europe Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
FRANCE |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
France Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
GERMANY |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
Germany Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
UNITED KINGDOM |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
UK Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
ASIA-PACIFIC |
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of World Historic Review for Orphan Drugs by Drug Type - Biologic Drugs and Non-biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of World 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologic Drugs and Non-biologic Drugs for the Years 2014, 2024 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of World Historic Review for Orphan Drugs by Disease Type - Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of World 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncological Diseases, Hematologic Diseases, Respiratory Diseases, Neurological Diseases, Cardiovascular Diseases, Endocrine Diseases and Other Disease Types for the Years 2014, 2024 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com